News for CytomX Therapeutics, Inc. (CTMX)

PR NewswireNEW YORK, July 9, 2025 NetworkNewsWire Editorial CoverageNEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are d

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. ( CTMX), a leader in the field of masked, conditionally activated biol

U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Wednesday. Shares of HEICO Corporation HEI rose sharply during Wednesday's ses...

CytomX Therapeutics, under the ticker (CTMX), has begun a new phase in its clinical trial by administering the first dose of CX-801 in combination with Merck's

SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. ( CTMX), a leader in the field of masked, conditionally activated biol

Analyst Joseph Catanzaro from Piper Sandler has revised the stock price target for CytomX Therapeutics (CTMX), raising it from $2.50 to $5.00. This reflects a 1

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Piper Sandler has significantly increased its price target for CytomX Therapeutics (CTMX), raising it to $5 from $2.50. This decision comes in the wake of the c

CytomX Therapeutics (CTMX) has seen its stock upgraded by H.C. Wainwright from Neutral to Buy, with a new price target set at $5, following the release of promi

CytomX Therapeutics reveals promising CX-2501 results & strengthens finances with $100M offering. Key updates on cancer trials & collaborations. Click to read.

May 12, 2025 / 12:00PM GMTOperator Good morning, everyone, and thank you for standing by. Welcome to the CytomX Therapeutics CX-2051 Phase 1 Interim Clinical Da

- Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Can

**media[614529]**

Piper Sandler has initiated coverage of CytomX Therapeutics (CTMX) with an optimistic outlook, assigning an Overweight rating to the stock. The investment firm

**media[572468]**

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

We recently compiled a list of the 10 Cheap Growth Stocks to Buy Now. In this article, we are going to take a look at where CytomX Therapeutics, Inc.

Cash, Cash Equivalents, and Investments: $100.6 million as of December 31, 2024.Revenue: $138.1 million for the full year 2024, up from $101.2 million in 2023.

Mar 06, 2025 / 10:00PM GMTOperator Good afternoon, everyone. Thank you for standing by. Welcome to the CytomX Therapeutics fourth-quarter 2024 and financial res